全文获取类型
收费全文 | 81篇 |
免费 | 1篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 1篇 |
基础医学 | 10篇 |
口腔科学 | 1篇 |
临床医学 | 8篇 |
内科学 | 36篇 |
特种医学 | 2篇 |
外科学 | 2篇 |
预防医学 | 2篇 |
眼科学 | 5篇 |
药学 | 3篇 |
肿瘤学 | 10篇 |
出版年
2022年 | 1篇 |
2021年 | 4篇 |
2020年 | 2篇 |
2018年 | 1篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 3篇 |
2014年 | 2篇 |
2013年 | 3篇 |
2012年 | 10篇 |
2011年 | 7篇 |
2009年 | 2篇 |
2008年 | 7篇 |
2007年 | 5篇 |
2006年 | 7篇 |
2005年 | 4篇 |
2004年 | 3篇 |
2003年 | 3篇 |
2001年 | 2篇 |
1999年 | 2篇 |
1998年 | 1篇 |
1995年 | 1篇 |
1984年 | 2篇 |
1982年 | 2篇 |
1978年 | 1篇 |
1977年 | 2篇 |
排序方式: 共有82条查询结果,搜索用时 15 毫秒
11.
Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity 总被引:2,自引:0,他引:2
Märten A von Lilienfeld-Toal M Büchler MW Schmidt J 《International journal of cancer. Journal international du cancer》2006,119(10):2359-2365
Intestinal cells express MHC related molecules termed MICA/MICB, which are up-regulated under stress and in many gastrointestinal tumors. These molecules can be recognized by the immunoreceptor NKG2D, which is present on NK and gammadelta T cells. Release of MIC molecules from the cell surface is thought to constitute an immune escape mechanism of tumor cells. The immediate effect of soluble MIC (sMIC) on cellular cytotoxicity of gammadelta T cells is yet not investigated. We determined sMIC levels in sera of patients with pancreatic carcinoma and the expression of MIC on the surface of tumor cells by FACS. The effect of sMIC content in patient serum on cellular cytotoxicity of gammadelta T and NK cells was investigated by cytotoxicity assays. Subsequently, the effect of IFN-alpha treatment on MIC expression, release and cellular cytotoxicity was investigated. Pancreatic carcinoma cells express MIC, and patient sera contain elevated sMIC levels that correlate with tumor stage and differentiation. Furthermore, cellular cytotoxicity of gammadelta T cells and NK cells against pancreatic carcinoma is impaired by sMIC in patient sera which is prevented by sMIC neutralization. Incubation of pancreatic cancer cells with IFN-alpha increases MIC expression without induction of sMIC resulting in enhanced lysis of tumor cells. Our results demonstrate that sMIC impairs NKG2D-mediated immunity against pancreatic carcinoma by directly diminishing cytotoxicity of gammadelta T cells and NK cells. IFN-alpha, which is used in adjuvant treatment of pancreatic carcinoma, might partly act via up-regulation of MIC without induction of sMIC release. 相似文献
12.
Fleischhacker M Schulz S J?hrens K von Lilienfeld-Toal M Held T Fietze E Schewe C Petersen I Ruhnke M 《Clinical microbiology and infection》2012,18(10):1010-1016
Hepatic Candida infection (HCI; known as chronic disseminated candidosis or CDC) is a distinct form of disseminated Candida infection with predominant involvement of the liver. Diagnosis of HCI is usually made on clinical suspicion together with multiple lesions in liver on ultrasound (US), CT and/or MRI scan. Fungal elements may not always be visible in liver tissue and mycological culture is frequently negative, making the evidence for proven fungal disease difficult. We studied a novel commercially available low-cost and density-array (LCD) chip technique for a molecular diagnosis of HCI. This is a two-step procedure with PCR amplification after DNA extraction followed by hybridization on a small chip provided by the manufacturer (Fungi 2.1, Chipron GmbH). The analysis of DNA from 45 fungal control strains showed an excellent specificity and sensitivity. The DNA from 11 liver biopsies of patients with haematological malignancies suffering from CDC was analysed on the LCD chip and overall 11 fungal pathogens could be detected in eight liver biopsies, supporting the clinical diagnosis of HCI/CDC. Analysis of liver biopsies from controls was negative for fungal DNA in all samples studied. In conclusion, the novel LCD chip technique examined in our study was able to detect fungal pathogens in liver biopsies from patients with haematological malignancies and suspected HCI/CDC but was negative in control biopsies. 相似文献
13.
Palumbo A Dimopoulos M San Miguel J Harousseau JL Attal M Hussein M Knop S Ludwig H von Lilienfeld-Toal M Sonneveld P 《Blood reviews》2009,23(2):87-93
Recent studies have shown a clinical benefit of lenalidomide, an oral immunomodulatory drug, plus dexamethasone in patients with relapsed/refractory multiple myeloma (MM). The most common grade 3-4 adverse events were cytopenias, fatigue, muscle cramps, rash, infection, insomnia, and venous thromboembolism. Lenalidomide in combination with dexamethasone has been approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of patients with MM who have received at least one prior therapy. An expert panel reviewed the efficacy and toxicity of lenalidomide plus dexamethasone, and provided recommendations on the management of patients receiving this treatment. Patient selection is straightforward, as prognostic factors do not appear to heavily influence efficacy. In addition, the panel agreed on strategies for the management of side effects. The recommendations presented here will aid the safe administration of lenalidomide, and avoid unnecessary dose reduction and discontinuation, thus assuring the best efficacy of treatment. 相似文献
14.
Vehreschild MJ Meissner AM Cornely OA Maschmeyer G Neumann S von Lilienfeld-Toal M Karthaus M Wattad M Staib P Hellmich M Christ H Vehreschild JJ 《Haematologica》2011,96(12):1855-1860
Background
Neutropenic patients are at risk of abdominal complications and yet the incidence and impact of these complications on patients’ morbidity and mortality have not been sufficiently evaluated. We aimed to assess a clinical rule for early detection of abdominal complications leading to death or transfer to intensive care in patients with chemotherapy-associated neutropenia.Design and Methods
This observational multicenter study was carried out in seven German hematology-oncology departments. For inclusion, neutropenia of at least 5 consecutive days was required. Risk factors for “transfer to intensive care” and “death” were assessed by backward-stepwise binary logistic regression analyses. Chemotherapy-associated bowel syndrome was defined as a combination of fever (T ≥37.8 °C) and abdominal pain and/or lack of bowel movement for 72 hours or more. Five hundred and twenty-one neutropenic episodes were documented in 359 patients.Results
The incidence of chemotherapy-associated bowel syndrome was 126/359 (35%) in first episodes of neutropenia. Transfer to intensive care occurred in 41/359 (11%) and death occurred in 17/359 (5%) first episodes. Chemotherapy-associated bowel syndrome and duration of neutropenia were identified as risk factors for transfer to intensive care (P<0.001; OR 4.753; 95% CI 2.297–9.833, and P=0.003; OR 1.061/d; 95% CI 1.021–1.103). Chemotherapy-associated bowel syndrome and mitoxantrone administration were identified as risk factors for death (P=0.005; OR 4.611; 95% CI 1.573–13.515 and P=0.026; OR 3.628; 95% CI 1.169–11.256).Conclusions
The occurrence of chemotherapy-associated bowel syndrome has a significant impact on patients’ outcome. In future interventional clinical trials, this definition might be used as a selection criterion for early treatment of patients at risk of severe complications. 相似文献15.
16.
17.
18.
散发性大肠癌肿瘤相关基因位点杂合性丢失分析 总被引:2,自引:1,他引:1
目的 分析大肠癌组织中抑癌基因及肿瘤相关基因位点的变化与预后的关系。方法 79例大肠癌组织经组织微解剖分离癌组织和正常组织,分别进行11 个染色体上14 个位点的杂合性丢失(lossofheterozygosity,LOH)分析。结果 肿瘤组织中LOH呈现一复杂的征象,5q12 及RB基因位点的LOH 与较好的预后有关。结论 不同的抑癌基因及肿瘤相关基因与大肠癌发生有关。5q12 位点的LOH 与较好预后相关的意义有待今后进一步研究。 相似文献
19.
20.